The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease

In chronic haemodialysis patients, anaemia is a frequent finding associated with high therapeutic costs and further expenses resulting from serial laboratory measurements. HemoHue HH1, HemoHue Ltd, is a novel tool consisting of a visual scale for the noninvasive assessment of anaemia by matching the...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert M. Kalicki, Stefan Farese, Dominik E. Uehlinger
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Anemia
Online Access:http://dx.doi.org/10.1155/2013/424076
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850223646481580032
author Robert M. Kalicki
Stefan Farese
Dominik E. Uehlinger
author_facet Robert M. Kalicki
Stefan Farese
Dominik E. Uehlinger
author_sort Robert M. Kalicki
collection DOAJ
description In chronic haemodialysis patients, anaemia is a frequent finding associated with high therapeutic costs and further expenses resulting from serial laboratory measurements. HemoHue HH1, HemoHue Ltd, is a novel tool consisting of a visual scale for the noninvasive assessment of anaemia by matching the coloration of the conjunctiva with a calibrated hue scale. The aim of the study was to investigate the usefulness of HemoHue in estimating individual haemoglobin concentrations and binary treatment outcomes in haemodialysis patients. A prospective blinded study with 80 hemodialysis patients comparing the visual haemoglobin assessment with the standard laboratory measurement was performed. Each patient’s haemoglobin concentration was estimated by seven different medical and nonmedical observers with variable degrees of clinical experience on two different occasions. The estimated population mean was close to the measured one (11.06 ± 1.67 versus 11.32 ± 1.23 g/dL, ). A learning effect could be detected. Relative errors in individual estimates reached, however, up to 50%. Insufficient performance in predicting binary outcomes (ROC AUC: 0.72 to 0.78) and poor interrater reliability (Kappa < 0.6) further characterised this method.
format Article
id doaj-art-43e44170f2ac4c4390094c26b69f2ee2
institution OA Journals
issn 2090-1267
2090-1275
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Anemia
spelling doaj-art-43e44170f2ac4c4390094c26b69f2ee22025-08-20T02:05:52ZengWileyAnemia2090-12672090-12752013-01-01201310.1155/2013/424076424076The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal DiseaseRobert M. Kalicki0Stefan Farese1Dominik E. Uehlinger2Department of Nephrology, Hypertension and Clinical Pharmacology, Inselspital Bern, University Hospital and University of Bern, Freiburgstrasse 15, 3010 Bern, SwitzerlandDepartment of Nephrology, Hypertension and Clinical Pharmacology, Inselspital Bern, University Hospital and University of Bern, Freiburgstrasse 15, 3010 Bern, SwitzerlandDepartment of Nephrology, Hypertension and Clinical Pharmacology, Inselspital Bern, University Hospital and University of Bern, Freiburgstrasse 15, 3010 Bern, SwitzerlandIn chronic haemodialysis patients, anaemia is a frequent finding associated with high therapeutic costs and further expenses resulting from serial laboratory measurements. HemoHue HH1, HemoHue Ltd, is a novel tool consisting of a visual scale for the noninvasive assessment of anaemia by matching the coloration of the conjunctiva with a calibrated hue scale. The aim of the study was to investigate the usefulness of HemoHue in estimating individual haemoglobin concentrations and binary treatment outcomes in haemodialysis patients. A prospective blinded study with 80 hemodialysis patients comparing the visual haemoglobin assessment with the standard laboratory measurement was performed. Each patient’s haemoglobin concentration was estimated by seven different medical and nonmedical observers with variable degrees of clinical experience on two different occasions. The estimated population mean was close to the measured one (11.06 ± 1.67 versus 11.32 ± 1.23 g/dL, ). A learning effect could be detected. Relative errors in individual estimates reached, however, up to 50%. Insufficient performance in predicting binary outcomes (ROC AUC: 0.72 to 0.78) and poor interrater reliability (Kappa < 0.6) further characterised this method.http://dx.doi.org/10.1155/2013/424076
spellingShingle Robert M. Kalicki
Stefan Farese
Dominik E. Uehlinger
The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease
Anemia
title The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease
title_full The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease
title_fullStr The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease
title_full_unstemmed The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease
title_short The Validation of a New Visual Anaemia Evaluation Tool HemoHue HH1 in Patients with End-Stage Renal Disease
title_sort validation of a new visual anaemia evaluation tool hemohue hh1 in patients with end stage renal disease
url http://dx.doi.org/10.1155/2013/424076
work_keys_str_mv AT robertmkalicki thevalidationofanewvisualanaemiaevaluationtoolhemohuehh1inpatientswithendstagerenaldisease
AT stefanfarese thevalidationofanewvisualanaemiaevaluationtoolhemohuehh1inpatientswithendstagerenaldisease
AT dominikeuehlinger thevalidationofanewvisualanaemiaevaluationtoolhemohuehh1inpatientswithendstagerenaldisease
AT robertmkalicki validationofanewvisualanaemiaevaluationtoolhemohuehh1inpatientswithendstagerenaldisease
AT stefanfarese validationofanewvisualanaemiaevaluationtoolhemohuehh1inpatientswithendstagerenaldisease
AT dominikeuehlinger validationofanewvisualanaemiaevaluationtoolhemohuehh1inpatientswithendstagerenaldisease